Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      Detectable disease and treatment in CLL can weigh heavily
      on patients' lives1

      Patient burden

      Click the tabs to reveal more about the burden of detectable disease and treatment in CLL

      *Leukaemia Survey of 2340 patients with leukaemia, including 1152 patients with CLL.1

      Explore deep response with VENCLYXTO

      References

      1. Leukaemia care. Living with Leukaemia. 2018 report.
      2. VENCLYXTO Summary of Product Characteristics.
      3. Seymour JF, et al. N Engl J Med 2018; 378(12): 1107–1120.
      4. Fischer K, et al. N Engl J Med 2019; 380: 2225-2236.
      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-210178. Date of preparation: June 2021.